IP Verse

Methods Of Treating Prostate Cancer - EP3490560

The patent EP3490560 was granted to Janssen Pharmaceutica on Jan 22, 2025. The application was originally filed on Jul 28, 2017 under application number EP17754226A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3490560

JANSSEN PHARMACEUTICA
Application Number
EP17754226A
Filing Date
Jul 28, 2017
Status
Granted And Under Opposition
Dec 20, 2024
Grant Date
Jan 22, 2025
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SANDOZSep 17, 2025ELKINGTON AND FIFEADMISSIBLE

Patent Citations (2) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS8071623
DESCRIPTIONUS8436185

Non-Patent Literature (NPL) Citations (22) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- cas, Database accession no. 915087-27-3, URL: stn-
DESCRIPTION- cas, Database accession no. 915087-33-1, URL: stn-
DESCRIPTION- cas, Database accession no. 956104-40-8, URL: stn-
EXAMINATION- Philip Jones ET AL, "Discovery of 2-{4-[(3 S )-Piperidin-3-yl]phenyl}-2 H -indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and -2 Mutant Tumors", Journal of Medicinal Chemistry, US, (20091126), vol. 52, no. 22, doi:10.1021/jm901188v, ISSN 0022-2623, pages 7170 - 7185, XP055263725
EXAMINATION- Michie Caroline Ogilvie ET AL, "Final results of the phase I trial of niraparib (MK4827), a poly(ADP)ribose polymerase (PARP) inhibitor incorporating proof of concept biomarker studies and expansion cohorts involving BRCA1/2 mutation carriers, sporadic ovarian, and castration resistant prostate cancer (CRPC).", Journal of Clinical Oncology, US, (20130520), vol. 31, no. 15_suppl, doi:10.1200/jco.2013.31.15_suppl.2513, ISSN 0732-183X, pages 2513 - 2513, XP093022104
INTERNATIONAL-SEARCH-REPORT- GRAS JORDI, "Niraparib hydrochloride. Poly [ADP-ribose] polymerase (PARP) inhibitor, Oncolytic", DRUGS OF THE FUTURE, PROUS SCIENCE, ES, (20131001), vol. 38, no. 10, doi:10.1358/DOF.2013.38.10.2059820, ISSN 0377-8282, pages 679 - 685, XP009195509 [X] 1,2,6,8,9 * page 683, column l, paragraph l - column r, paragraph 1 * [I] 3-5,7,10,11
OPPOSITION- Anonymous, "A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AMS)", ClinicalTrials.gov, U.S. National Library of Medicine, (20130725), XP093071664-
OPPOSITION- Anonymous, "Janssen Announces Preliminary Results from Phase 2 GALAHAD Study in Adults with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Pathway Defects (DRD)", (20190214), XP093071757-
OPPOSITION- Anonymous, "Monetizing Focus: Tesaro Adds Runway By Out-licensing Niraparib In Prostate Cancer", The Pink Sheet Daily, Pharma Intelligence UK Limited (Citeline), (20160406), pages 1 - 3, The Pink Sheet Daily, URL: https://pink.pharmaintelligence.informa.com/PS079383, (20240129), XP093124841-
OPPOSITION- Vignani Francesca; Tambaro Rosa; De Giorgi Ugo; Giannatempo Patrizia; Bimbatti Davide; Carella Claudia; Stellato Marco; Atzori Francesco; Aieta Michele; Masini Cristina; Hamzaj Alketa; Ermacora Paola; Veccia Antonello; Scandurra Giuseppa; Gamba Teresa; Ignazzi Gianluca; Pignata Sandro; Di Napoli Marilena; Lolli Cristian; Procopio Giuseppe; Pierantoni Francesco; Zonno Antonia; Santini Daniele; Di Maio Massimo, "Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial", European Urology, Elsevier, AMSTERDAM, NL, AMSTERDAM, NL , (20221008), vol. 83, no. 1, doi:10.1016/j.eururo.2022.09.025, ISSN 0302-2838, pages 82 - 89, XP087225415
OPPOSITION- Park Sook Ryun, Chen Alice, "Poly(Adenosine Diphosphate-Ribose) Polymerase Inhibitors in Cancer Treatment", HEMATOLOGY - ONCOLOGY CLINICS OF NORTH AMERICA, W.B. SAUNDERS, US, US , (20120601), vol. 26, no. 3, doi:10.1016/j.hoc.2012.02.012, ISSN 0889-8588, pages 649 - 670, XP093317775
OPPOSITION- Shahneen K Sandhu, William R Schelman, George Wilding, Victor Moreno, Richard D Baird, Susana Miranda, Lucy Hylands, Ruth Riisnaes, Martin Forster, Aurelius Omlin, Nathan Kreischer, Khin Thway, Heidrun Gevensleben, Linda Sun, John Loughney, Manash Chatterjee, Carlo Toniatti, Christopher L Carpenter, Robert Iannone, Stan B Kaye, Johann S De Bono, Robert M Wenham, "The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial", The Lancet Oncology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20130801), vol. 14, no. 9, doi:10.1016/S1470-2045(13)70240-7, pages 882 - 892, XP055407449
OPPOSITION- P. Jones et al., "Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination", Journal of Medicinal Chemistry, (2015), vol. 58, doi:10.1021/jm5018237, XP055855855
OPPOSITION- P. Jones et al., "Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and -2 Mutant Tumors", J. Med. Chem., (2009), vol. 52, doi:10.1021/jm901188v, XP055263725
OPPOSITION- H.E. Bryant et al., "Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase", Nature, (2005), vol. 434, doi:10.1038/nature03443, XP007906257
OPPOSITION- H. Farmer et al., "Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy", Nature, (2005), vol. 434, doi:10.1038/nature03445, XP002516395
OPPOSITION- Peter C. Fong, David S. Boss, Timothy A. Yap, Andrew Tutt, Peijun Wu, Marja Mergui-Roelvink, Peter Mortimer, Helen Swaisland, Alan Lau, Mark J. O'Connor, Alan Ashworth, James Carmichael, Stan B. Kaye, Jan H.M. Schellens, Johann S. de Bono, "Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers", The new England journal of medicine, Eli Lily and Company, USA, USA, (20090709), vol. 361, no. 2, doi:10.1056/NEJMoa0900212, pages 123 - 134, XP003030947
OPPOSITION- Michie Caroline Ogilvie, Sandhu Shahneen Kaur, Schelman William R., Molife L Rhoda, Wilding George, Omlin Aurelius Gabriel, Kansra Vikram, Brooks David G., Martell Robert E., Kaye Stanley B., De Bono Johann Sebastian, Wenham Robert Michael, "Final results of the phase I trial of niraparib (MK4827), a poly(ADP)ribose polymerase (PARP) inhibitor incorporating proof of concept biomarker studies and expansion cohorts involving BRCA1/2 mutation carriers, sporadic ovarian, and castration resistant prostate cancer (CRPC).", Journal of Clinical Oncology, (20130520), vol. 31, no. 15_suppl, doi:10.1200/jco.2013.31.15_suppl.2513, pages 2513 - 2513, XP093022104
OPPOSITION- Flores John Paul, Mathew Paul, "Combination therapy with enzalutamide and the poly (ADP-ribose) polymerase-1 (PARP1) inhibitor niraparib in castration-resistant prostate cancer (CRPC): HCRN GU 14-202.", 2024 ASCO Gastrointestinal Cancers Symposium, American Society of Clinical Oncology, Poster L3, Poster L3, (20160520), vol. 34, no. 15_suppl, doi:10.1200/JCO.2016.34.15_suppl.TPS5095, ISSN 0732-183X, pages TPS5095 - TPS5095, XP093317781
OPPOSITION- Chi Kim N, Rathkopf Dana, Smith Matthew R, Efstathiou Eleni, Attard Gerhardt, Olmos David, Ji ;, Lee Youl, Small Eric J, Pereira De Andrea J, Gomes Santana, Roubaud Guilhem, Saad Marniza, Zurawski Bogdan, Sakalo Valerii, Mason Gary E, Francis Peter, Wang George, Wu Daphne, Diorio Brooke, Lopez-Gitlitz Angela, Sandhu Shahneen, "Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer", doi:10.1200/JCO.22, (20230323), pages 1 - 15, (20230808), XP093071658
OPPOSITION- Gras Jordi, "Niraparib hydrochloride. Poly [ADP-ribose] polymerase (PARP) inhibitor, Oncolytic.", Drugs of the Future, Prous Science, ES, ES , (20131001), vol. 38, no. 10, doi:10.1358/dof.2013.38.10.2059820, ISSN 0377-8282, pages 679 - 685, XP009195509
OPPOSITION- J. Zhang, "Poly (ADP‑ribose) polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer", Asian Journal of Andrology, (2014), vol. 16, doi:10.4103/1008-682X.123684, XP055472262

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents